Santero Therapeutics develops novel therapeutics targeting antibiotic-resistant pathogens through unique mechanisms of action derived from over a decade of foundational research. The company addresses the critical challenge of rising antibiotic resistance, which renders previously treatable bacterial infections increasingly difficult to manage.
Funding
$9.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NBFounders
Product
Problem
The rise of antibiotic-resistant pathogens poses a significant threat to global health, rendering many previously treatable bacterial infections increasingly difficult to manage with existing antibiotics. This resistance necessitates the development of new therapeutic strategies with unique mechanisms of action.
Solution
Santero Therapeutics is developing innovative drugs with novel mechanisms of action to combat highly resistant pathogens. Leveraging over a decade of foundational research, the company aims to deliver therapeutics that can overcome existing resistance mechanisms. These new drugs target bacterial survival to stress and antibiotic resistance, offering a potential solution to infections that are becoming increasingly difficult to treat.
Target Audience
The primary target audience includes patients with bacterial infections resistant to existing antibiotics, as well as healthcare providers seeking new treatment options for these infections.
Features
- Focus on novel mechanisms of action to bypass existing antibiotic resistance.
- Targets bacterial survival mechanisms to stress.
- Development of new therapeutics against bacterial infections.